Product image of Jimandin (Sitagliptin) supplied by GNH India

Jimandin

Active Ingredient:
Sitagliptin
Origin:
EU

Jimandin (Sitagliptin)

Sitagliptin, the active ingredient in Jimandin, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antidiabetic agents are insufficient to achieve glycaemic control.

GNH India supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and global distribution.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is a DPP‑4 inhibitor used to improve glycaemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By preventing this degradation, sitagliptin increases circulating levels of GLP‑1 and GIP, leading to glucose‑dependent stimulation of insulin secretion, suppression of glucagon release, and delayed gastric emptying, thereby lowering post‑prandial and fasting blood glucose concentrations.

Side Effects

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the upper airway.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Nausea: occasional mild stomach upset.
  • Diarrhoea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: autoimmune blistering skin disorder.
  • Hepatic injury: elevated liver enzymes or hepatitis.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use.

  • Renal function: assess renal impairment and adjust dose if necessary.
  • Hepatic impairment: monitor liver function in patients with existing liver disease.
  • Cardiovascular disease: use cautiously in patients with a history of heart failure.
  • Elderly patients: start at lower dose and monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks.
  • Store below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Co‑administration with other DPP‑4 inhibitors: may increase risk of adverse effects without added benefit.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels.
  • Diuretics (e.g., furosemide): may enhance risk of dehydration and renal impairment.
  • Rifampin: may reduce sitagliptin exposure; consider dose adjustment.

Frequently Asked Questions

Jimandin contains sitagliptin, a DPP‑4 inhibitor that is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents have not achieved target glycaemic levels.

Sitagliptin blocks the DPP‑4 enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher levels of these hormones stimulate insulin release and suppress glucagon in a glucose‑dependent manner, which helps lower both fasting and post‑prandial blood glucose.

The appropriate dose of Jimandin is determined by the prescribing healthcare professional based on the individual’s renal function, concomitant medications, and overall treatment plan. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To request Jimandin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike sulfonylureas or insulin, sitagliptin does not directly stimulate insulin release; it enhances the body’s own incretin response, resulting in a lower risk of hypoglycaemia when used alone. It is also weight‑neutral, whereas some other agents may cause weight gain or loss.

Jimandin tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Jimandin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, although rare, include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, bullous pemphigoid, and significant liver injury. Any sudden, severe abdominal pain or signs of an allergic reaction require immediate medical evaluation.

Jimandin should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation, and in those with a history of pancreatitis. Caution is also advised for individuals with severe renal impairment where dose adjustment may be required.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT